AZ's tozorakimab shows broad COPD benefits ahead of FDA priority review

AZ’s IL-33 inhibitor tozorakimab delivered meaningful reductions in COPD exacerbations in two pivotal trials (Oberon and Titania), cutting moderate/severe attacks by about 29–34% in former smokers and around 30% overall in current/former smokers. Benefits extended across eosinophil subgroups and included a mucus plug score reduction, suggesting broad, differentiated efficacy. The company has secured FDA priority review, positioning tozorakimab as a potential flagship COPD biologic as it competes with other pipeline therapies.